{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:30:28Z","timestamp":1790692228132,"version":"4.1.0"},"reference-count":209,"publisher":"Elsevier","isbn-type":[{"value":"9780323983921","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.acr.2022.03.002","type":"book-chapter","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T19:06:06Z","timestamp":1648321566000},"page":"367-413","source":"Crossref","is-referenced-by-count":16,"title":["Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acr.2022.03.002_bb0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1034\/j.1600-0528.2002.017415.x","article-title":"Physiological responses of extrathymic T cells in the liver","volume":"174","author":"Abo","year":"2000","journal-title":"Immunological Reviews"},{"issue":"4_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA","volume":"40","author":"Abou-Alfa","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.acr.2022.03.002_bb0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","article-title":"The role of cancer-associated fibroblasts and fibrosis in liver cancer","volume":"12","author":"Affo","year":"2017","journal-title":"Annual Review of Pathology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0025","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00262-019-02299-8","article-title":"The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma","volume":"68","author":"Agdashian","year":"2019","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0030","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41590-018-0114-2","article-title":"Tissue-resident memory T cells at the center of immunity to solid tumors","volume":"19","author":"Amsen","year":"2018","journal-title":"Nature Immunology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3892\/ol.2021.13122","article-title":"Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population","volume":"23","author":"Ando","year":"2022","journal-title":"Oncology Letters"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0040","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: A phase II study","volume":"99","author":"Andre","year":"2008","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.acr.2022.03.002_bb0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2019.04.005","article-title":"Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer","volume":"132","author":"Assoun","year":"2019","journal-title":"Lung Cancer"},{"issue":"23","key":"10.1016\/bs.acr.2022.03.002_bb0050","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1158\/1078-0432.CCR-20-1497","article-title":"Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma","volume":"26","author":"Bassaganyas","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.002_bb0055","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.002_bb0060","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1002\/eji.200636033","article-title":"Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance","volume":"36","author":"Berg","year":"2006","journal-title":"European Journal of Immunology"},{"issue":"15_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0065","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1200\/JCO.2021.39.15_suppl.2564","article-title":"Antitumor activity of dostarlimab in patients with mismatch repair-deficient\/microsatellite instability\u2013high tumors: A combined analysis of two cohorts in the GARNET study","volume":"39","author":"Berton","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.002_bb0070","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nature Immunology"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.002_bb0075","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.4049\/jimmunol.0711086","article-title":"Enrichment of human CD4+ V(alpha)24\/Vbeta11 invariant NKT cells in intrahepatic malignant tumors","volume":"182","author":"Bricard","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/bs.acr.2022.03.002_bb0080","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nature Communications"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.002_bb0085","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00262-018-2190-4","article-title":"Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma","volume":"67","author":"Brown","year":"2018","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"16 Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0090","doi-asserted-by":"crossref","first-page":"LB-094","DOI":"10.1158\/1538-7445.AM2020-LB-094","article-title":"Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma","volume":"80","author":"Buonaguro","year":"2020","journal-title":"Cancer Research"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0095","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jhep.2021.01.017","article-title":"Expression of NKG2D ligands is downregulated by beta-catenin signalling and associates with HCC aggressiveness","volume":"74","author":"Cadoux","year":"2021","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0100","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2017.05.014","article-title":"Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification","volume":"67","author":"Calderaro","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","article-title":"Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma","volume":"70","author":"Calderaro","year":"2019","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0110","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2014.11.007","article-title":"MDA5 plays a critical role in interferon response during hepatitis C virus infection","volume":"62","author":"Cao","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1016\/bs.acr.2022.03.002_bb0115","article-title":"Intrahepatic cholangiocarcinoma: Genomic heterogeneity between eastern and Western patients","volume":"4","author":"Cao","year":"2020","journal-title":"JCO Precision Oncology"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.002_bb0120","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.molmed.2019.06.007","article-title":"Immunomodulatory TGF-beta signaling in hepatocellular carcinoma","volume":"25","author":"Chen","year":"2019","journal-title":"Trends in Molecular Medicine"},{"issue":"12","key":"10.1016\/bs.acr.2022.03.002_bb0125","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"The Journal of Experimental Medicine"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.002_bb0130","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1158\/2159-8290.CD-16-0329","article-title":"Polarization of tissue-resident TFH-like cells in human hepatoma bridges innate monocyte inflammation and M2b macrophage polarization","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.acr.2022.03.002_bb0135","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","author":"Cheng","year":"2021","journal-title":"The Journal of Hepatology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","article-title":"Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function","volume":"32","author":"Condamine","year":"2011","journal-title":"Trends in Immunology"},{"key":"10.1016\/bs.acr.2022.03.002_bb0145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.021908.132629","article-title":"The liver as a lymphoid organ","volume":"27","author":"Crispe","year":"2009","journal-title":"Annual Review of Immunology"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.002_bb0150","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1084\/jem.20072076","article-title":"Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection","volume":"205","author":"Das","year":"2008","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/bs.acr.2022.03.002_bb0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clim.2017.10.002","article-title":"Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens","volume":"187","author":"DeFalco","year":"2018","journal-title":"Clinical Immunology"},{"issue":"4_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0160","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/JCO.2020.38.4_suppl.574","article-title":"NTRK gene fusions in biliary tract cancers","volume":"38","author":"Demols","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.002_bb0165","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-13-2590","article-title":"Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers","volume":"20","author":"Di Caro","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0170","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.21965","article-title":"Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance","volume":"47","author":"Diehl","year":"2008","journal-title":"Hepatology"},{"issue":"27","key":"10.1016\/bs.acr.2022.03.002_bb0175","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","article-title":"Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures","volume":"26","author":"Dieu-Nosjean","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.acr.2022.03.002_bb0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1034\/j.1600-0528.2002.017416.x","article-title":"Innate and adaptive lymphoid cells in the human liver","volume":"174","author":"Doherty","year":"2000","journal-title":"Immunological Reviews"},{"issue":"10088","key":"10.1016\/bs.acr.2022.03.002_bb0185","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"3_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0190","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.2021.39.3_suppl.269","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040","volume":"39","author":"El-Khoueiry","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0195","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1158\/1078-0432.CCR-19-2337","article-title":"Antidrug antibodies against immune checkpoint blockers: Impairment of drug efficacy or indication of immune activation?","volume":"26","author":"Enrico","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"5464","key":"10.1016\/bs.acr.2022.03.002_bb0200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.288.5464.339","article-title":"The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies","volume":"288","author":"Farci","year":"2000","journal-title":"Science"},{"issue":"20","key":"10.1016\/bs.acr.2022.03.002_bb0205","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1002\/cncr.32339","article-title":"Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma","volume":"125","author":"Feun","year":"2019","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/bs.acr.2022.03.002_bb0210","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/ni.3290","article-title":"Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma","volume":"16","author":"Finkin","year":"2015","journal-title":"Nature Immunology"},{"issue":"26","key":"10.1016\/bs.acr.2022.03.002_bb0215","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"20","key":"10.1016\/bs.acr.2022.03.002_bb0220","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"3_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0225","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.002_bb0235","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumor environment by TGFbeta","volume":"10","author":"Flavell","year":"2010","journal-title":"Nature Reviews. Immunology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0240","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/hep.26731","article-title":"Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma","volume":"59","author":"Flecken","year":"2014","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.002_bb0245","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0250","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nature Reviews. Immunology"},{"issue":"18","key":"10.1016\/bs.acr.2022.03.002_bb0255","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","article-title":"Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection","volume":"25","author":"Gao","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.002_bb0260","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2013.206","article-title":"BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma","volume":"27","author":"Goeppert","year":"2014","journal-title":"Modern Pathology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0265","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2016.05.020","article-title":"Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma","volume":"30","author":"Gomes","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acr.2022.03.002_bb0270","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2407-10-209","article-title":"A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma","volume":"10","author":"Greten","year":"2010","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0275","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.26694","article-title":"Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma","volume":"59","author":"Han","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/bs.acr.2022.03.002_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.547013","article-title":"Hepatocarcinoma induces a tumor necrosis factor-dependent Kupffer cell death pathway that Favors its proliferation upon partial hepatectomy","volume":"10","author":"Hastir","year":"2020","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0290","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jhep.2016.07.048","article-title":"High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease","volume":"66","author":"Hedegaard","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010077","article-title":"Immune therapy for liver cancers","volume":"12","author":"Hilmi","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.002_bb0300","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nature Cancer"},{"key":"10.1016\/bs.acr.2022.03.002_bb0305","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fimmu.2018.00151","article-title":"The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy","volume":"9","author":"Hornyak","year":"2018","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0310","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0782","article-title":"Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment","volume":"4","author":"Horwitz","year":"2014","journal-title":"Cancer Discovery"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0315","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2019.08.014","article-title":"The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications","volume":"72","author":"Hou","year":"2020","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0320","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3748\/wjg.v8.i4.654","article-title":"HLA class I expression in primary hepatocellular carcinoma","volume":"8","author":"Huang","year":"2002","journal-title":"World Journal of Gastroenterology"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.002_bb0325","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3748\/wjg.v27.i5.404","article-title":"Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy","volume":"27","author":"Huang","year":"2021","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/bs.acr.2022.03.002_bb0330","article-title":"Mechanisms and clinical trials of hepatocellular carcinoma immunotherapy","volume":"12","author":"Huang","year":"2021","journal-title":"Frontiers in Genetics"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0335","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ni.2573","article-title":"Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection","volume":"14","author":"Huang","year":"2013","journal-title":"Nature Immunology"},{"key":"10.1016\/bs.acr.2022.03.002_bb0340","article-title":"The landscape of immune cells indicates prognosis and applicability of checkpoint therapy in hepatocellular carcinoma","volume":"11","author":"Huang","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0345","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/cncr.26456","article-title":"Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer","volume":"118","author":"Ilie","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0350","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00280-009-1069-7","article-title":"Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: A Korean Cancer Study Group phase II trial","volume":"65","author":"Jang","year":"2010","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.002_bb0355","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ni.2691","article-title":"Immune surveillance by the liver","volume":"14","author":"Jenne","year":"2013","journal-title":"Nature Immunology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0360","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.27822","article-title":"Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma","volume":"62","author":"Ji","year":"2015","journal-title":"Hepatology"},{"issue":"38","key":"10.1016\/bs.acr.2022.03.002_bb0365","doi-asserted-by":"crossref","first-page":"41339","DOI":"10.18632\/oncotarget.5463","article-title":"A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0370","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ijc.10966","article-title":"Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid","volume":"104","author":"Jinushi","year":"2003","journal-title":"International Journal of Cancer"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.002_bb0375","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.tranon.2019.04.021","article-title":"The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review","volume":"12","author":"Juengpanich","year":"2019","journal-title":"Translational Oncology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0380","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/annonc\/mdx076","article-title":"Pembrolizumab KEYNOTE-001: An adaptive study leading to accelerated approval for two indications and a companion diagnostic","volume":"28","author":"Kang","year":"2017","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.002_bb0385","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2013.06.010","article-title":"Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma","volume":"59","author":"Kapanadze","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"27","key":"10.1016\/bs.acr.2022.03.002_bb0390","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0395","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.annonc.2021.10.008","article-title":"VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial","volume":"33","author":"Kelley","year":"2022","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0400","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2013.08.007","article-title":"CD141(+) myeloid dendritic cells are enriched in healthy human liver","volume":"60","author":"Kelly","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0405","doi-asserted-by":"crossref","first-page":"206","DOI":"10.14701\/ahbps.2021.25.2.206","article-title":"Adjuvant therapy using ex vivo-expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study","volume":"25","author":"Kim","year":"2021","journal-title":"Annals of Hepato-Biliary-Pancreatic Surgery"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0410","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of Nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0415","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00280-008-0883-7","article-title":"A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer","volume":"64","author":"Kim","year":"2009","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0420","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ni1428","article-title":"Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice","volume":"8","author":"Kim","year":"2007","journal-title":"Nature Immunology"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.002_bb0425","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of combination nivolumab and Ipilimumab immunotherapy in patients with advanced biliary tract cancers: Subgroup analysis of a phase 2 nonrandomized clinical trial","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0430","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4049\/jimmunol.162.3.1401","article-title":"Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells","volume":"162","author":"Knolle","year":"1999","journal-title":"Journal of Immunology"},{"issue":"37\u201338","key":"10.1016\/bs.acr.2022.03.002_bb0435","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4414\/smw.2003.10261","article-title":"Control of immune responses by savenger liver endothelial cells","volume":"133","author":"Knolle","year":"2003","journal-title":"Swiss Medical Weekly"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.002_bb0440","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/j.gastro.2013.12.036","article-title":"Hepatic immune regulation and its involvement in viral hepatitis infection","volume":"146","author":"Knolle","year":"2014","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.002_bb0445","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","article-title":"Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial","volume":"23","author":"Knox","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1016\/bs.acr.2022.03.002_bb0450","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1200\/JCO.2008.16.5704","article-title":"Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: A multicenter, phase II trial of the Swiss Group for Clinical Cancer Research","volume":"26","author":"Koeberle","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0455","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ccr.2008.12.018","article-title":"Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment","volume":"15","author":"Kortylewski","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0460","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/ni.1990","article-title":"IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses","volume":"12","author":"Krausgruber","year":"2011","journal-title":"Nature Immunology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0465","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.4049\/jimmunol.0904094","article-title":"Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients","volume":"185","author":"Kuang","year":"2010","journal-title":"Journal of Immunology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0470","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.20082173","article-title":"Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1","volume":"206","author":"Kuang","year":"2009","journal-title":"The Journal of Experimental Medicine"},{"issue":"7101","key":"10.1016\/bs.acr.2022.03.002_bb0475","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumor incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0480","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nature Reviews. Cancer"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.002_bb0485","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"148","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0490","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): An open-label, multicentre, phase 1b study","volume":"21","author":"Lee","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"6468","key":"10.1016\/bs.acr.2022.03.002_bb0495","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"10.1016\/bs.acr.2022.03.002_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.01.029","article-title":"Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions","author":"Leslie","year":"2022","journal-title":"Journal of Hepatology"},{"issue":"12","key":"10.1016\/bs.acr.2022.03.002_bb0505","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1111\/cas.13811","article-title":"Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma","volume":"109","author":"Li","year":"2018","journal-title":"Cancer Science"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0510","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4049\/jimmunol.1502615","article-title":"Tolerogenic phenotype of IFN-gamma-induced IDO+ dendritic cells is maintained via an autocrine IDO-kynurenine\/AhR-IDO loop","volume":"197","author":"Li","year":"2016","journal-title":"Journal of Immunology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0515","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jhep.2010.07.044","article-title":"Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection","volume":"54","author":"Li","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.002_bb0520","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1172\/JCI134402","article-title":"Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy","volume":"130","author":"Li","year":"2020","journal-title":"The Journal of Clinical Investigation"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.002_bb0525","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"issue":"12","key":"10.1016\/bs.acr.2022.03.002_bb0530","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/82161","article-title":"Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance","volume":"6","author":"Limmer","year":"2000","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0535","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cell.2010.02.021","article-title":"Th17 and regulatory T cells in mediating and restraining inflammation","volume":"140","author":"Littman","year":"2010","journal-title":"Cell"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0540","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/hep.28020","article-title":"Chemokine (C-X-C motif) receptor 3-positive B cells link interleukin-17 inflammation to protumorigenic macrophage polarization in human hepatocellular carcinoma","volume":"62","author":"Liu","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0545","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41416-018-0144-4","article-title":"Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma","volume":"119","author":"Liu","year":"2018","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.acr.2022.03.002_bb0550","article-title":"Immunotherapies for hepatocellular carcinoma","author":"Llovet","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"15_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0555","doi-asserted-by":"crossref","first-page":"TPS4152","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4152","article-title":"Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study","volume":"37","author":"Llovet","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0560","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0565","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/hep.1840080207","article-title":"Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis","volume":"8","author":"Lumsden","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/bs.acr.2022.03.002_bb0570","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2271","article-title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumors","volume":"31","author":"Lwin","year":"2020","journal-title":"Annals of Oncology"},{"issue":"6391","key":"10.1016\/bs.acr.2022.03.002_bb0575","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"issue":"7593","key":"10.1016\/bs.acr.2022.03.002_bb0580","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"10.1016\/bs.acr.2022.03.002_bb0585","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.768009","article-title":"Biliary tract cancers: Treatment updates and future directions in the era of precision medicine and Immuno-oncology","volume":"11","author":"Manne","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040926","article-title":"Natural killer cell responses in hepatocellular carcinoma: Implications for novel immunotherapeutic approaches","volume":"12","author":"Mantovani","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.002_bb0595","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumor mutational burden with outcomes in patients with advanced solid tumors treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0605","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/hep.25965","article-title":"TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis","volume":"57","author":"Matsubara","year":"2013","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.002_bb0610","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/MEG.0000000000001821","article-title":"Fibrosis improvement in patients with HCV treated with direct-acting antivirals","volume":"33","author":"McPhail","year":"2021","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"3_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0615","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2021.39.3_suppl.268","article-title":"Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study","volume":"39","author":"Merle","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1016\/bs.acr.2022.03.002_bb0620","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1158\/0008-5472.CAN-09-4672","article-title":"Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes","volume":"70","author":"Movahedi","year":"2010","journal-title":"Cancer Research"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.002_bb0625","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumor angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nature Reviews. Cancer"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.002_bb0630","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/sj.bjc.6600543","article-title":"Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: A prospective phase II trial","volume":"87","author":"Nehls","year":"2002","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0635","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjc.6604178","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: A prospective multicentre phase II trial","volume":"98","author":"Nehls","year":"2008","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0640","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00281-009-0173-4","article-title":"Microanatomy of the liver immune system","volume":"31","author":"Nemeth","year":"2009","journal-title":"Seminars in Immunopathology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0645","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2008.08.008","article-title":"NK and NKT cells in liver injury and fibrosis","volume":"130","author":"Notas","year":"2009","journal-title":"Clinical Immunology"},{"issue":"4_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0650","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"15_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0655","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/JCO.2020.38.15_suppl.4520","article-title":"Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) \u00b1 tremelimumab (T) and gemcitabine\/cisplatin (GemCis) in chemo-na\u00efve advanced biliary tract cancer (aBTC)","volume":"38","author":"Oh","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1016\/bs.acr.2022.03.002_bb0660","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.4161\/cc.5.15.3112","article-title":"Stromal fibroblasts in cancer: A novel tumor-promoting cell type","volume":"5","author":"Orimo","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/bs.acr.2022.03.002_bb0665","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1038\/ncomms13453","article-title":"Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma","volume":"7","author":"Ouyang","year":"2016","journal-title":"Nature Communications"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.002_bb0670","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200050","article-title":"Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes","volume":"217","author":"Pallett","year":"2020","journal-title":"The Journal of Experimental Medicine"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0675","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nm.3856","article-title":"Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells","volume":"21","author":"Pallett","year":"2015","journal-title":"Nature Medicine"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.002_bb0680","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.4049\/jimmunol.1400725","article-title":"Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells","volume":"193","author":"Pardee","year":"2014","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0685","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/01926230590522365","article-title":"Liver immunobiology","volume":"33","author":"Parker","year":"2005","journal-title":"Toxicologic Pathology"},{"issue":"6506","key":"10.1016\/bs.acr.2022.03.002_bb0690","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1126\/science.aay2767","article-title":"BTN3A1 governs antitumor responses by coordinating alphabeta and gammadelta T cells","volume":"369","author":"Payne","year":"2020","journal-title":"Science"},{"issue":"7854","key":"10.1016\/bs.acr.2022.03.002_bb0695","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumor surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.002_bb0700","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0705","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for advanced hepatocellular carcinoma: A focus on special subgroups","volume":"70","author":"Pinter","year":"2021","journal-title":"Gut"},{"issue":"12","key":"10.1016\/bs.acr.2022.03.002_bb0710","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"issue":"4_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0715","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","article-title":"Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study","volume":"40","author":"Qin","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"2 Suppl. 1","key":"10.1016\/bs.acr.2022.03.002_bb0720","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1002\/hep.21060","article-title":"The liver as an immunological organ","volume":"43","author":"Racanelli","year":"2006","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/bs.acr.2022.03.002_bb0725","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0730","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jhep.2019.08.017","article-title":"Advances in molecular classification and precision oncology in hepatocellular carcinoma","volume":"72","author":"Rebouissou","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/bs.acr.2022.03.002_bb0735","article-title":"BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update","author":"Reig","year":"2021","journal-title":"The Journal of Hepatology"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.002_bb0740","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"The Lancet Oncology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0745","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/cncr.22902","article-title":"Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer","volume":"110","author":"Riechelmann","year":"2007","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0750","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2004.08.013","article-title":"Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma","volume":"41","author":"Ritter","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"6230","key":"10.1016\/bs.acr.2022.03.002_bb0755","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0760","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","article-title":"L-arginine availability regulates T-lymphocyte cell-cycle progression","volume":"109","author":"Rodriguez","year":"2007","journal-title":"Blood"},{"issue":"7749","key":"10.1016\/bs.acr.2022.03.002_bb0765","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.002_bb0770","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"Beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discovery"},{"issue":"15_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0775","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1200\/JCO.2020.38.15_suppl.4582","article-title":"A multicenter randomized phase II study of nivolumab in combination with gemcitabine\/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01)","volume":"38","author":"Sahai","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0780","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","article-title":"Paradigms on immunotherapy combinations with chemotherapy","volume":"11","author":"Salas-Benito","year":"2021","journal-title":"Cancer Discovery"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0785","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic Signaling pathways in the Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0790","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jhep.2021.10.021","article-title":"Reply to: \"An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously\"","volume":"76","author":"Sangro","year":"2022","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0795","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0800","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"Journal of Hepatology"},{"issue":"13","key":"10.1016\/bs.acr.2022.03.002_bb0805","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"7680","key":"10.1016\/bs.acr.2022.03.002_bb0810","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature24302","article-title":"Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity","volume":"551","author":"Shalapour","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.002_bb0815","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1136\/gutjnl-2020-320716","article-title":"Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma","volume":"70","author":"Shang","year":"2021","journal-title":"Gut"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.002_bb0820","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00432-010-0833-8","article-title":"Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma","volume":"136","author":"Shen","year":"2010","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0825","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death Receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.002_bb0830","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.tcb.2008.06.003","article-title":"Role of myeloid cells in tumor angiogenesis and growth","volume":"18","author":"Shojaei","year":"2008","journal-title":"Trends in Cell Biology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0835","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0840","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.002_bb0845","first-page":"62","article-title":"Biliary carcinomas: Pathology and the role of DNA mismatch repair deficiency","volume":"5","author":"Silva","year":"2016","journal-title":"Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0850","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41421-020-00214-5","article-title":"Global immune characterization of HBV\/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression","volume":"6","author":"Song","year":"2020","journal-title":"Cell Discovery"},{"issue":"12","key":"10.1016\/bs.acr.2022.03.002_bb0855","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123830","article-title":"Clinical and genetic tumor characteristics of responding and non-responding patients to PD-1 inhibition in hepatocellular carcinoma","volume":"12","author":"Spahn","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7559","key":"10.1016\/bs.acr.2022.03.002_bb0860","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumor immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.002_bb0865","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s00262-012-1278-5","article-title":"B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence","volume":"61","author":"Sun","year":"2012","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0870","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","article-title":"Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma","volume":"184","author":"Sun","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0875","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1264562","article-title":"High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer","volume":"6","author":"Sun","year":"2017","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.002_bb0880","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1488564","article-title":"Potentiating cancer vaccine efficacy in liver cancer","volume":"7","author":"Tagliamonte","year":"2018","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0885","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/1440-1681.12689","article-title":"A tumor-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways","volume":"44","author":"Tan","year":"2017","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.002_bb0890","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/hep.510250511","article-title":"Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma","volume":"25","author":"Tatsumi","year":"1997","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/bs.acr.2022.03.002_bb0895","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-20-1319","article-title":"IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy","volume":"27","author":"Teijeira","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"4_Suppl","key":"10.1016\/bs.acr.2022.03.002_bb0900","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1200\/JCO.2022.40.4_suppl.470","article-title":"IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study","volume":"40","author":"Toh","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"10272","key":"10.1016\/bs.acr.2022.03.002_bb0905","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/bs.acr.2022.03.002_bb0910","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0915","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/hep.29914","article-title":"Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis","volume":"68","author":"van der Windt","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0920","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13543784.2021.1868437","article-title":"Immunotherapies in clinical development for biliary tract cancer","volume":"30","author":"Vogel","year":"2021","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/bs.acr.2022.03.002_bb0925","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcell.2020.00055","article-title":"The function of the HGF\/c-met Axis in hepatocellular carcinoma","volume":"8","author":"Wang","year":"2020","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0930","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3892\/ijo.2011.1295","article-title":"Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy","volume":"40","author":"Wang","year":"2012","journal-title":"International Journal of Oncology"},{"issue":"6","key":"10.1016\/bs.acr.2022.03.002_bb0935","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3109\/07357907.2014.909826","article-title":"B7-H3 was highly expressed in human primary hepatocellular carcinoma and promoted tumor progression","volume":"32","author":"Wang","year":"2014","journal-title":"Cancer Investigation"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0940","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2006-01-0177","article-title":"Regulatory T-cell compartmentalization and trafficking","volume":"108","author":"Wei","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.002_bb0945","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"Wheeler","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.acr.2022.03.002_bb0950","doi-asserted-by":"crossref","first-page":"15050","DOI":"10.1038\/ncomms15050","article-title":"TCF1(+) hepatitis C virus-specific CD8(+) T cells are maintained after cessation of chronic antigen stimulation","volume":"8","author":"Wieland","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/bs.acr.2022.03.002_bb0955","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3389\/fphys.2020.00990","article-title":"The role of sinusoidal endothelial cells in the axis of inflammation and cancer within the liver","volume":"11","author":"Wilkinson","year":"2020","journal-title":"Frontiers in Physiology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0960","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0965","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/hep.26192","article-title":"Monocyte\/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48\/2B4 interactions","volume":"57","author":"Wu","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/bs.acr.2022.03.002_bb0970","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2567.2009.03179.x","article-title":"Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific","volume":"129","author":"Wu","year":"2010","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/bs.acr.2022.03.002_bb0975","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","article-title":"PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression","volume":"6","author":"Xiao","year":"2016","journal-title":"Cancer Discovery"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb0980","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-018-0321-2","article-title":"Translation control of the immune checkpoint in cancer and its therapeutic targeting","volume":"25","author":"Xu","year":"2019","journal-title":"Nature Medicine"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.002_bb0985","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus Ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib: The CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2022.03.002_bb0990","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"The Lancet Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb0995","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/hep.31862","article-title":"Molecular characterization of biliary tract cancer predicts chemotherapy and programmed death 1\/programmed death-ligand 1 blockade responses","volume":"74","author":"Yoon","year":"2021","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.002_bb1000","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00262-020-02561-4","article-title":"Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma","volume":"69","author":"Zecca","year":"2020","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"4","key":"10.1016\/bs.acr.2022.03.002_bb1005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and dynamics of single immune cells in hepatocellular carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"issue":"10","key":"10.1016\/bs.acr.2022.03.002_bb1010","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/cmi.2016.28","article-title":"Liver-infiltrating CD11b(\u2212)CD27(\u2212) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression","volume":"14","author":"Zhang","year":"2017","journal-title":"Cellular & Molecular Immunology"},{"issue":"8","key":"10.1016\/bs.acr.2022.03.002_bb1015","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/eji.201041282","article-title":"Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients","volume":"41","author":"Zhao","year":"2011","journal-title":"European Journal of Immunology"},{"issue":"2","key":"10.1016\/bs.acr.2022.03.002_bb1020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/labinvest.2013.139","article-title":"Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model","volume":"94","author":"Zhao","year":"2014","journal-title":"Laboratory Investigation"},{"issue":"11","key":"10.1016\/bs.acr.2022.03.002_bb1025","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/ijc.25920","article-title":"Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice","volume":"129","author":"Zhao","year":"2011","journal-title":"International Journal of Cancer"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.002_bb1030","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.acr.2022.03.002_bb1035","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fphys.2018.00452","article-title":"Galectin-9 expression predicts favorable clinical outcome in solid tumors: A systematic review and meta-analysis","volume":"9","author":"Zhou","year":"2018","journal-title":"Frontiers in Physiology"},{"issue":"7","key":"10.1016\/bs.acr.2022.03.002_bb1040","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"The Lancet Oncology"},{"issue":"16 Suppl","key":"10.1016\/bs.acr.2022.03.002_bb1045","doi-asserted-by":"crossref","first-page":"CT044","DOI":"10.1158\/1538-7445.AM2020-CT044","article-title":"Abstract CT044: Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)","volume":"80","author":"Zhu","year":"2020","journal-title":"Cancer Research"},{"issue":"16","key":"10.1016\/bs.acr.2022.03.002_bb1050","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1200\/JCO.2007.15.6521","article-title":"High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma","volume":"26","author":"Zhu","year":"2008","journal-title":"Journal of Clinical Oncology"}],"container-title":["Advances in Cancer Research","Hepatobiliary Cancers: Translational Advances and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X22000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X22000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:06:10Z","timestamp":1762229170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X22000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323983921"],"references-count":209,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2022.03.002","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}